New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE".

Thromboembolic Venous Disease Clinical Trial

— Fit-Génétique  

Official title:

Search for New Mutations Genetic Predisposing to an Increased Risk Venous Thromboembolic Disease Idiopathic. Study "FIT GENETIQUE".

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02841085
• Other study ID #: RB 09.058 Fit Génétique
• Status: Completed
• Start date: May 27, 2010
• Est. completion date: May 14, 2021

Study information

• Verified date: March 2022
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Identify new genetic mutations predisposing to an increased risk of VTE by locating and / or identifying genes involved in subjects at high risk for thrombotic and in whom screening for detectable hereditary thrombophilia was negative.

Description:

Venous thromboembolism desease is a public health problem justifying major primary and secondary prevention policy. When VTE occurs in the absence of risk factor clinically identifiable ( "idiopathic"), an inherited biological risk factor ( "inherited thrombophilia") is found in 30% of cases. However, in patients with idiopathic VTE, the risk of recurrent venous thromboembolism is very high, whether detectable inherited thrombophilia was found or not.

This first observation suggests that patients with idiopathic VTE and no detectable thrombophilia are likely to have an underlying unknown thrombophilia that are yet to be discovered.

This hypothesis is further supported by the results of the study "FIT" (Regional PHRC 2001, promoter CHU Brest, Investigator Main: Francis Couturaud, EA3878 Brest, France, and investigator Associate: Clive Kearon, McMaster University, Hamilton, Ontario, Canada), a cross international study evaluating the risk of VTE among the family members first degree of patients a first idiopathic VTE episode. In this large study cross-1950 family members first degree (topics study) of 372 patients with a first episode of VTE Idiopathic (propositi) were included (50% included in Brest and 50% inclusive in Canada). The main result is that the risk of VTE among family members first degree is high and similar, the proband either bearer or without a detectable hereditary thrombophilia. In other words, even in the absence of detectable hereditary thrombophilia, the risk of VTE among family members first degree is high. This study has identified the subjects in that it is likely they have an inherited thrombophilia which has not yet been discovered.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 613
• Est. completion date: May 14, 2021
• Est. primary completion date: May 14, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• Family members in the 1st, 2nd, 3rd and 4th degree (and their spouses if they have a descent) of patients (propositi) who:

1. / have a single episode of unprovoked venous thromboembolic disease without detectable inherited and acquired thrombophilia ;

2. / were included in the "FIT" study;

3. / consenting that their family members 2nd, 3rd and 4th degree are approached to participate in the this study.

• Written Consent of propositi and their members in the 2nd, 3rd and 4th respective degree to participate in this study.

Exclusion Criteria:

• Presence of detectable thrombophilia in the propositi.

• Presence of hereditary thrombophilia or detectable gained at family members.

• No information may be obtained on previous venous thromboembolism among family members on 1 degree

• Everything about the study (depending on the population and members of proband Family 1st, 2nd, 3rd and 4th degree) less than 15 years.

• The family member is an adopted child

Related Conditions & MeSH terms

• Thromboembolic Venous Disease

Intervention

Genetic:
• Genetic sample
Blood sample or saliva collection

Locations

Country	Name	City	State
France	CHRU de Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Research of new genetic mutations	Identify new genetic mutations predisposing risk increased Thromboembolic Venous Disease by locating and / or identifying the genes involved in subjects at high risk for thrombotic and in whom screening for detectable inherited or acquired thrombophilia was negative.; was negative.	1 day
Secondary	Quantify the presence of new thrombophilia hereditary risk of Thromboembolic Venous Disease	Quantify the importance of the presence of new thrombophilia hereditary risk of Thromboembolic Venous Disease.	1 day